Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

Bayer to Develop Hemophilia Gene Therapy Treatment

Dimension Therapeutics, a Cambridge biotechnology startup, has struck a deal worth up to $252 million with the pharmaceutical giant Bayer HealthCare to develop a gene therapy to treat hemophilia, a rare disease that prevents blood from clotting. The goal of the prospective treatment, which is not yet in clinical trials, is to repair a faulty […]

Industry News

FDA Approves Biogen Idec’s ELOCATE™, First Long Lasting Hemophilia A Therapy

– Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Infusions Every Three to Five Days – – Approval of Biogen Idec’s Second Innovative Hemophilia Therapy with Prolonged Circulation This Year – Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved ELOCTATE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein] […]

Industry News

Bayer Hemophilia Awards Program (BHAP) Recipients

Harvard Stem Cell Institute Affiliated Faculty member Juan Melero-Martin, PhD, at Boston Children’s Hospital is one of the 2014 grant recipients of the Bayer Hemophilia Awards Program (BHAP), a unique initiative dedicated to supporting innovative research and educational initiatives that benefit people with hemophilia. This year, Bayer Healthcare awarded more than $2 million in funding […]

Industry News

FDA Approves Bayer’s Kogenate® FS for Adult Prophylaxis

Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer’s Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. The approval is based on data from the SPINART study, in which 84 patients […]

Biogen Idec and Sobi To Donate $1 Billion Units of Clotting Factor

Biogen Idec and Swedish Orphan Biovitrum AB announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation […]

CSL Opens World-Class Manufacturing Facility for Hemophilia Therapies

CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site’s manufacturing plant for plasma products, is the centerpiece of CSL’s $250 million expansion at its Broadmeadows site and will play […]

Grifols Donates Coagulation Medicines to World Federation of Hemophilia

Grifols announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a decade – and this unprecedented product donation represents its largest […]

Reuters: Biogen Idec Hemophilia Drug Prices On Par With Older Therapies

Reuters – Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually. The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide […]

FDA approves First Long-Acting Recombinant Factor IX for Hemophilia B

The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. Alprolix is approved to help control […]

Wall Street Journal: The Hemophilia Drug at the Core of Baxter’s Pharma Spin-Off

Will the Baxter International bioscience spin-out become a bleeder by relying too heavily on hemophilia treatments? This is a key question being sorted out as the health care products company prepares to split into two entities next year. In 2013, Baxter’s hemophilia business amounted to $3.4 billion, or slightly more than 58 percent of the […]

Page 5 of 1712345678910NextLast »

Assisting and Advocating for the Bleeding Disorders Community